HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (27) Citing Articles via Google Scholar Google Scholar Articles by Breidbach, A. Articles by Gorzek, J. Search for Related Content PubMed PubMed Citation Articles by Breidbach, A. Articles by Gorzek, J. Related Collections Proteomics and Protein Markers Drug Monitoring and Toxicology Endocrinology and Metabolism

Detection of Recombinant Human Erythropoietin in Urine by Isoelectric Focusing

¹ UCLA Olympic Analytical Laboratory,
² Department of Family Medicine, Division of Sports Medicine, and
³ Department of Molecular and Medical Pharmacology, University of California at Los Angeles, Los Angeles, CA 90025.

^aAddress correspondence to this author at: UCLA Olympic Analytical Laboratory, 2122 Granville Ave., Los Angeles, CA 90025. Fax 310-205-9177; e-mail Dcatlin{at}ucla.edu.

Background: Doping with erythropoietic proteins such as recombinant human erythropoietin (rHuEPO) and darbepoetin alfa is a serious issue in sport. There is little information on the time course of detection of rHuEPO in urine and on methods to evaluate electrophoresis-based data.

Methods: We used a recently described isoelectric focusing method for detecting rHuEPO and endogenous EPO in urine obtained from individuals treated with placebo or epoetin alfa. The latter was administered subcutaneously at 50 IU/kg on days 0, 2, 4, 7, 9, 11, 14, 16, and 18. Blood and urine samples were collected during the morning of study days -3, 0, 2, 4, 7, 9, 11, 14, 16, and 18 and on days 2, 3, 4, and 7 postadministration. We developed visual and numerical (two-band ratio) techniques to evaluate the electropherograms for the presence of rHuEPO.

Results: Compared with the placebo group, the epoetin alfa-treated group responded with increases in hematocrit, reticulocytes, macrocytes, serum EPO, and serum soluble transferrin receptor. The electropherograms showed that the pattern of bands arising from urinary rHuEPO is different from that of endogenous urinary EPO. Both the two-band ratio and the visual technique detected rHuEPO in all 14 epoetin alfa-treated individuals 3 days after the last dose. On the 7th day after the last dose, both techniques detected rHuEPO in approximately one-half of the participants. rHuEPO was not detected in the placebo-treated individuals.

Conclusions: The isoelectric focusing method detects rHuEPO in most urine samples collected 3 days after nine doses of epoetin alfa. The numerical two-band ratio was equivalent to a visual method for detecting rHuEPO in urine.

The following articles in journals at HighWire Press have cited this article:

				M. Beullens, J. R. Delanghe, and M. Bollen False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise Blood, June 15, 2006; 107(12): 4711 - 4713. [Abstract] [Full Text] [PDF]

				G. Lippi and G. Guidi New Scenarios in Antidoping Research Clin. Chem., December 1, 2003; 49(12): 2106 - 2107. [Full Text] [PDF]